Table 3.
Construct | Amino acid substitution(s) | Epoxiconazole |
Tebuconazole |
Triadimenol |
Prochloraz |
Prothioconazole |
Propiconazole |
Cycloheximide |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EC50 | RF | EC50 | RF | EC50 | RF | EC50 | RF | EC50 | RF | EC50 | RF | EC50 | RF | ||
pYES2-Mg51wt | None | 0.0019 ± 0.0002 | 1 | 0.0055 ± 0.0019 | 1 | 0.046 ± 0.0036 | 1 | 0.0047 ± 0.001 | 1 | 0.041 ± 0.014 | 1 | 0.0037 ± 0.0005 | 1 | 0.055 ± 0.0049 | 1 |
pYES2-Mg51S524T | S524T | 0.017 ± 0.0009 | 9 | 0.099 ± 0.0034 | 18 | 0.684 ± 0.092 | 15 | 0.055 ± 0.007 | 12 | 1.36 ± 0.75 | 33 | 0.036 ± 0.044 | 10 | 0.063 ± 0.0045 | 1 |
pYES2-Mg51Y137F/S524T | Y137F, S524T | 0.025 ± 0.019 | 13 | 0.19 ± 0.11 | 34 | 18.3 ± 1.23 | 398 | 0.306 ± 0.137 | 65 | 0.093 ± 0.009 | 2 | 0.056 ± 0.006 | 15 | 0.058 ± 0.0022 | 1 |
pYES2-Mg51L50S/Y461S | L50S, Y461S | 0.0121 ± 0.0056 | 6 | 0.287 ± 0.015 | 52 | 2.06 ± 0.68 | 44 | 0.069 ± 0.027 | 14 | 0.073 ± 0.002 | 2 | 0.043 ± 0.016 | 12 | 0.067 ± 0.024 | 1 |
pYES2-Mg51L50S/Y461S/S524T | L50S, Y461S, S524T | 0.181 ± 0.024 | 95 | 3.48 ± 0.27 | 632 | >50 ± NR | >1,080 | 0.64 ± 0.075 | 136 | 1.15 ± 0.29 | 28 | 1.37 ± 0.39 | 370 | 0.071 ± 0.003 | 1 |
pYES2-L50S/D134G/V136A/Y461S | L50S, D134G, V136A, Y461S | 0.019 ± 0.012 | 10 | 0.016 ± 0.003 | 3 | 0.574 ± 0.24 | 12 | 0.087 ± 0.004 | 19 | 0.148 ± 0.011 | 4 | 0.0093 ± 0.002 | 3 | 0.063 ± 0.008 | 1 |
pYES2-L50S/D134G/V136A/Y461S/S524T | L50S, D134G, V136A, Y461S, S524T | 0.38 ± 0.18 | 200 | 0.42 ± 0.049 | 76 | >50 ± NR | >1,080 | 3.92 ± 0.71 | 834 | 14.3 ± 1.67 | 349 | 4.49 ± 1.09 | 1,200 | 0.066 ± 0.007 | 1 |
EC50 (mg liter−1) are the means of two independent replicates ± standard deviations. Mean resistance factors (RF) of transformants are calculated as the fold changes in EC50 compared to EC50 of transformants expressing wild-type MgCYP51 (pYES2-Mg51wt). NR, no result.